INT273497

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.02
First Reported 2009
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 1
Disease Relevance 0.36
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (IMPDH2) small molecule metabolic process (IMPDH2) oxidoreductase activity (IMPDH2)
RNA binding (IMPDH2) nucleus (IMPDH2) DNA binding (IMPDH2)
Anatomy Link Frequency
kidney 1
IMPDH2 (Homo sapiens)
Pain Link Frequency Relevance Heat
withdrawal 29 5.00 Very Low Very Low Very Low
corticosteroid 6 5.00 Very Low Very Low Very Low
abdominal pain 2 5.00 Very Low Very Low Very Low
Bile 1 5.00 Very Low Very Low Very Low
tolerance 1 5.00 Very Low Very Low Very Low
fibrosis 1 5.00 Very Low Very Low Very Low
Inflammation 1 5.00 Very Low Very Low Very Low
Tetrahydrobiopterin 1 5.00 Very Low Very Low Very Low
antagonist 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Bacterial Respiratory Disease 1 99.46 Very High Very High Very High
Organ Transplantation 2 95.44 Very High Very High Very High
Toxicity 3 79.72 Quite High
Renal Failure 24 5.00 Very Low Very Low Very Low
Death 7 5.00 Very Low Very Low Very Low
Infection 6 5.00 Very Low Very Low Very Low
Cytomegalovirus Infection 5 5.00 Very Low Very Low Very Low
Vomiting 4 5.00 Very Low Very Low Very Low
Malignant Neoplastic Disease 3 5.00 Very Low Very Low Very Low
Graft Vs Host Disease 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Mycophenolic acid (MPA) is a fermentation product of Penicillium brevicompactum and related fungi.1 It was discovered by Gosio in 1893 and was shown to have weak antibacterial activity.2 Its ability to inhibit inosine-5’-monophosphate dehydrogenase (IMPDH) was first identified in 1969.3 Initial studies with MMF in animal models of organ transplantation yielded encouraging results and led to the initiation of human trials.4,5 Sollinger et al conducted the first human trial of MMF in 1992 in kidney transplant recipients.6 Since then, MMF has been used in combination with other medications to prevent acute rejections, for rescue treatment in acute rejection episodes and as adjuvant to facilitate “sparing” of other immunosuppressive agents.


Negative_regulation (inhibit) of inosine-5 in kidney associated with bacterial respiratory disease and organ transplantation
1) Confidence 0.02 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697521 Disease Relevance 0.36 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox